Don't mistake Stryker's latest $500 million deal in the spine market as a simple tuck-in acquisition, says one analyst while another says it could help Stryker give Medtronic a run for its money.
After diabetes, Medtronic is looking to leverage AI through a distribution agreement with Viz.ai, which uses the technology to streamline stroke care.
The home care industry is booming. As Baby Boomers age and more families seek in-home solutions for loved ones, demand for home care services is at an all-time high.
The San Diego-based company has is in the midst of one of the most precipitous turnarounds in the medical device industry and is well positioned to grow alongside the expanding insulin pump market.
Medtronic announced data at the annual meeting of the American Diabetes Association on Monday that shows that people using its AI-powered Sugar.IQ diabetes assistant have better control of their blood glucose levels.
On the day that an FDA official exhorts industry to develop interoperable diabetes devices, Medtronic announces that it is teaming up with a nonprofit group to do just that.
MedCity News caught up with Omron Healthcare CEO Ranndy Kellogg at the the AdvaMed Digital MedTech Conference in San Francisco to speak about the company's new products, emerging business lines and how collaboration with other companies have driven recent innovation.
Break down the silos. Take control of your provider data.
Dexcom's executives lay out the land in terms of competition in the standalone continuous glucose monitoring market while Medtronic CEO responds.
While the development of renal denervation technologies stalled after a failed Medtronic study in 2014, recent positive research results have led to increasing interest - and investment - in the space.
Medtronic said the company will be rolled into its Diabetes Group to improve its diabetes management capabilities by adding Nutrino's comprehensive food database, food analysis system and nutrition-science expertise.
An expensive failed acquisition, sales force flux, off-label use of a controversial biologics product, a DOJ investigation and nimble competitors chipping away has hobbled Medtronic's spine business. The purchase of Mazor Robotics aims to be a major reset.
A new report by Paubox calls for healthcare IT leaders to dispose of outdated assumptions about email security and address the challenges of evolving cybersecurity threats.
In less than a decade, the chief patient officer - and similar roles with different titles - has become a key part of the healthcare industry executive team.
Medtronic had previously betted on higher adoption of its insulin pumps tethering the use of continuous glucose monitors to those pumps but has recently returned to the standalone CGM market with the launch of its Guardian Connect device in the U.S. Should Dexcom and Abbott worry?
In a bid to expand into the larger, more lucrative type 2 diabetes market, the medical device maker offers a performance guarantee to payers and employers tied to its MiniMed 670G insulin pump system.
With the FDA approval of a new continuous glucose monitoring system with machine learning capabilities to predict highs and lows in blood-glucose levels, Medtronic makes a bigger play for type 2 diabetes patients.
After a Type 1 patient penned a post on why she didn't think Medtronic's 670G hailed as the first artificial pancreas was all that, another patient who uses the device writes it's exactly that and then some.